We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Researchers from Moscow’s Gamaleya Research Institute have posted results from two phase 1/2 trials of their controversial COVID-19 vaccine, showing it was safe and induced the production of antibodies in all adult volunteers. Read More
The U.S. may be gearing up for vaccine distribution, but a World Health Organization (WHO) spokesperson said Friday that the international agency doesn’t expect to see widespread vaccination with a COVID-19 vaccine until the middle of next year, stressing that more time is needed for late-stage clinical trials. Read More
Yeliva is currently in mid-to-late stage testing globally for hospitalized patients with severe COVID-19 pneumonia who require supplemental oxygen. Read More
RedHill Biopharma has announced positive steps in two late-stage trials evaluating its Yeliva (opaganib) for severe COVID-19 patients and said it plans to file an Emergency Use Authorization (EUA) for the drug as early as the end of the year. Read More
An independent Safety Monitoring committee has recommended the continuation of a phase 2 trial in the U.S., studying the drug in 40 severe COVID-19 patients. Read More
An analysis of seven international clinical trials published yesterday found that corticosteroids help reduce the risk of death in the most severe COVID-19 patients. Read More
Sanofi and Regeneron Pharmaceuticals said they have no plans to conduct further trials of their rheumatoid arthritis drug Kevzara for COVID-19 after it failed in a late-stage study. Read More